← BACK halfmarble halfmarble 02 // PK
SteadyDoseTracker — Pharmacokinetic Visualizer
Bateman model: C(t) = A(e-ke·t - e-ka·t) — click chart to set NOW, then add doses
Y-axis: 100% = peak concentration of one full dose taken fasting · therapeutic min ~25%, dyskinesia ~80%
THIS TOOL VISUALIZES — IT DOES NOT PRESCRIBE. It mathematically models the decay of the medication schedule your doctor already prescribed. It does not account for individual physiology, drug interactions, or clinical context. No output is medical advice. Always consult your physician before making any changes to your medication schedule.
2:00 PM NOW — drag on chart to move
Activity Demand — click/drag to paint
Calendar → Demand (demo)
In the real app, this reads your phone's calendar automatically. Here, add events to see how your day's activities shape the demand curve above.
Eating Windows — meals marked PROTEIN reduce levodopa absorption
Meal 1 11:00 AM – 11:30 AM
Meal 2 5:00 PM – 5:30 PM
Meal 3 8:00 PM – 8:30 PM
DYSKINESIA TOLERANCE
Dose Log
DOSES TODAY 0
CURRENT LEVEL 0%
TIME IN RANGE
NEXT DOSE IN
VARIABILITY ±50%
Expected blood concentration (Bateman equation)
Confidence band (population variability in absorption & elimination)
Therapeutic window (effective range without dyskinesia)
Circadian zones — morning peak (best absorption), afternoon dip (wearing off risk), wind-down
Activity demand — modulates therapeutic window (higher demand = higher coverage needed)
Eating window — reduced levodopa absorption (protein competes for LNAA transport)
Glass Box // what the AI reads

No black box. Every paper and data source behind the pharmacokinetic model is listed here. You see what the math sees — nothing hidden, nothing invented. The source code will be released for independent review.

ANCHORED The PK model is pinned to published pharmacokinetic parameters — not a drifting LLM. The math cannot silently change between updates.
ON-DEVICE The PK model runs on your phone. No cloud. No server. All computation is local.
LOCAL Your dose logs and subjective reports stay on your phone by default. Join the fight beyond your own case: opt in to share anonymized, aggregated patterns with researchers — never your identity, never automatic, never without consent. See exactly what gets shared →
TRACEABLE Every parameter in the Bateman equation traces to a published source below. If it's not in the Glass Box, the model won't use it.
Pharmacokinetic Model Sources
01 Pharmacokinetics of levodopa Nutt & Fellman — Clinical Neuropharmacology, 1984
02 IPX066 (Rytary): pharmacokinetics of extended-release carbidopa-levodopa Hauser et al. — Lancet Neurology, 2013
03 Continuous dopaminergic stimulation in Parkinson's disease Olanow et al. — The Lancet Neurology, 2006
04 Population pharmacokinetics of levodopa in Parkinson's disease patients Clinical Pharmacokinetics, 2020 DOI PENDING
05 Sinemet CR pharmacokinetics: bioavailability and absorption characteristics Yeh et al. — Neurology, 1989 DOI PENDING
06 Effect of food on the pharmacokinetics of levodopa formulations Baruzzi et al. — Clinical Neuropharmacology, 1987 DOI PENDING
07 VYALEV (foslevodopa/foscarbidopa) — Full Prescribing Information AbbVie — FDA approved Oct 2024
08 VYALEV — Medication Guide (patient-facing) AbbVie
09 vyalev.com — Product information & Vyafuser pump usage AbbVie
Clinical Framework
10 Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial Phillips et al. — Movement Disorders, 2018
11 Wearing off and motor complications in Parkinson's disease Stocchi et al. — Neurology, 2010 DOI PENDING
12 Motor fluctuations and dyskinesia in Parkinson's disease: clinical guide and practical tips Vijayakumar & Jankovic — Drugs, 2016 DOI PENDING
13 Bateman, H. — The solution of a system of differential equations in pharmacokinetics Proc. Cambridge Phil. Soc., 1910
Simulation Parameters Derived From
Levodopa IR: t½ 90 min, Tmax 30-60 min, F=99% — from FDA prescribing label + Nutt & Fellman (1984)
Levodopa CR: t½ 90 min, Tmax 120 min, F=71% — from FDA prescribing label + Yeh et al. (1989)
Levodopa ER (dual-phase): 60% fast / 40% slow, Tmax 1h/4h — from Hauser et al. (2013) + FDA label
Foslevodopa/foscarbidopa SC infusion: continuous wearable pump, ~20-min cycles, F≈100% (subcutaneous, bypasses first-pass) — from prescribing info (citation #07)
Food effect: high-protein meals delay Tmax by ~30 min, reduce Cmax — from competitive amino acid transport literature
GLASS_BOX_POLICY: Every parameter in this simulation traces to a published pharmacokinetic source. The Bateman equation is the standard one-compartment oral absorption model used in clinical pharmacology. No proprietary algorithms. No hidden tuning. No synthetic data.
Join the fight